○Toshiya Ishihara, Tomoko Oeda, Satoshi Tomita, Atsushi Umemura, Masayuki Kohsaka, Kwiyoung Park, Masayuki Tahara, Kenji Yamamoto, Hiroshi Sugiyama, Hideyuki Sawada (Department of Neurology, Utano National Hospital, Kyoto, Japan)
Session information
Oral Session
[O-11] Parkinsonism and Related disorders (Drug discovery)
Wed. May 23, 2018 3:25 PM - 4:25 PM Room 13 (Royton Sapporo / Crystal Room C (2F))
Chair: Yoshio Tsuboi(Department of Neurology)
○Ikuko Aiba1, Takeshi Ikeuchi2, Hiroshi Takigawa3, Takahiko Tokuda4, Takayoshi Shimohata5, Mitsuya Morita6, Shigeo Murayama7, Osamu Onodera8, Kazuko Hasegawa9, Hisanori Kowa10, Ritsuko Hanajima3, Nakashima Kenji10, JALPAC consortium2 (1.Depatrment of Neurology, National Hospital Organization, Higashinagoya National Hospital, 2.Molecular Genetics, Brain Research Institute, Niigata University, 3.Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, 4.Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, 5.Depatrment of Neurology and Geriatrics, Gifu University Graduate School of Medicine, 6.Division of Neurology, Department of Internal Medicine, Jichi Medical University, 7.Department of Neurology and Neuropathology (the Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 8.Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, 9.Department of Neurology, National Hospital Organization, Sagamihara National Hospital, 10.Department of Neurology, National Hospital Organization, Matsue Medical Center)
○Takayasu Mishima1,2, Shinsuke Fujioka1, Hiroyuki Tomiyama3, Ichiro Yabe4, Ryoichi Kurisaki5, Naoki Fujii6, Ryuji Neshige7, Owen A. Ross2,8, Matthew J. Farrer9, Dennis W. Dickson2, Zbigniew K. Wszolek10, Nobutaka Hattori3, Yoshio Tsuboi1 (1.Department of Neurology, Fukuoka University School of Medicine, 2.Department of Neuroscience, Mayo Clinic, 3.Department of Neurology, Juntendo University School of Medicine, 4.Department of Neurology, Hokkaido University Graduate School of Medicine, 5.Department of Neurology, Kumamoto Saishunso National Hospital, 6.Department of Neurology, National Hospital Organization Omuta Hospital, 7.Neshige Neurological Clinic, 8.Department of Clinical Genomics, Mayo Clinic, 9.Department of Medical Genetics, University of British Columbia, 10.Department of Neurology, Mayo Clinic)
○Akio Kikuchi1, Michinori Ezura1, Nobuyuki Okamura2, Takafumi Hasegawa1, Aiko Ishiki3, Ryuichi Harada4, Naoto Sugeno1, Shun Yoshida1, Junpei Kobayashi1, Hiroyuki Arai3, Kazuhiko Yanai4, Shozo Furumoto5, Manabu Tashiro6, Yukitsuka Kudo3, Atsushi Takeda7, Masashi Aoki1 (1.Department of Neurology, Tohoku University Graduate School of Medicine, 2.Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 3.Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, 4.Department of Pharmacology, Tohoku University Graduate School of Medicine, 5.Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, 6.Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, 7.Department of Neurology, National Hospital Organization, Sendai Nishitaga Hospital)